Clinical trial
Enbrel Liquid Immunogenicity Protocol
NCT00249041 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00249041 |
|---|---|
| Title | Enbrel Liquid Immunogenicity Protocol |
| Official title | Open-label Study to Assess the Antibody Response to Etanercept Liquid in Subjects With Rheumatoid Arthritis (RA) |
| Lead sponsor | Amgen, Industry |
| Collaborators | Immunex Corporation Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | 50 mg Etanercept, Enbrel liquid |
| Enrollment | 447 |
| Start date | Oct 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Nov 7, 2005 |
| Last update posted | Jul 30, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: